Login to Your Account



Growth Opportunities 'Unclear'

Onyx Tumbles on Disappointing Nexavar Data in NSCLC Patients

By Jennifer Boggs


Wednesday, February 20, 2008
The impressive 2007 sales growth of cancer drug Nexavar, which increased 125 percent over the year before, was overshadowed by the early termination of an ongoing Phase III study of the drug in non-small-cell lung cancer (NSCLC) due to lack of efficacy, news that sent shares of Onyx Pharmaceuticals Inc. falling 26.4 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription